Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, Open-Label, Single Arm trial investigating the outcomes of neoadjuvant
FOLFIRINOX chemotherapy in patients with hepatic or pulmonary oligometastatic pancreatic
adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins